Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

"Our discussions with physicians as ASH were universally positive regarding the risk/benefit for Iclusig and indicating continuing demand for the drug as a 3rd line agent for CML. We forecast resumption of commercial distribution in the US in 2Q14 with a black box warning label indicating increased risk of CV events, in line with the November EMA recommendation of risk factor assessment before treatment and monitoring during treatment.,” Stifel Nicolaus’ analyst commented.
http://tickerreport.com/banking-finance/87849/ariad-pharmaceuticals-rating-increased-to-buy-at-stifel-nicolaus-aria/

Stifel Nicolaus upgraded ARIA from a Hold to a Buy with a price target of $7 based on the overwhelming support that docs at ASH showed for using Iclusig in a salvage population.